Equities analysts expect that Johnson & Johnson (NYSE:JNJ) will post $1.72 earnings per share for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for Johnson & Johnson’s earnings, with the lowest EPS estimate coming in at $1.69 and the highest estimate coming in at $1.77. Johnson & Johnson posted earnings per share of $1.58 in the same quarter last year, which suggests a positive year over year growth rate of 8.9%. The company is expected to issue its next quarterly earnings results on Tuesday, January 23rd.

According to Zacks, analysts expect that Johnson & Johnson will report full-year earnings of $7.27 per share for the current fiscal year, with EPS estimates ranging from $7.20 to $7.30. For the next fiscal year, analysts anticipate that the business will post earnings of $7.80 per share, with EPS estimates ranging from $7.50 to $8.18. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow Johnson & Johnson.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.68% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the previous year, the company posted $1.68 EPS. The firm’s revenue for the quarter was up 10.3% compared to the same quarter last year.

JNJ has been the topic of a number of research reports. Morgan Stanley raised their price target on Johnson & Johnson from $135.00 to $140.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 5th. Cowen and Company set a $147.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a research note on Thursday, August 24th. UBS AG restated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research note on Thursday, August 31st. BidaskClub downgraded Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st. Finally, Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Wednesday, October 4th. Five investment analysts have rated the stock with a sell rating, nine have issued a hold rating and ten have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $141.39.

Shares of Johnson & Johnson (NYSE JNJ) opened at 140.68 on Thursday. Johnson & Johnson has a 1-year low of $109.32 and a 1-year high of $141.58. The company’s 50 day moving average price is $133.17 and its 200-day moving average price is $130.54. The company has a market capitalization of $377.58 billion, a price-to-earnings ratio of 23.80 and a beta of 0.78.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a $0.84 dividend. The ex-dividend date is Monday, November 27th. This represents a $3.36 annualized dividend and a dividend yield of 2.39%. Johnson & Johnson’s payout ratio is 58.33%.

COPYRIGHT VIOLATION NOTICE: This report was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and republished in violation of US & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/johnson-johnson-jnj-expected-to-post-earnings-of-1-72-per-share/1640859.html.

In other news, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $133.14, for a total value of $13,672,412.88. Following the transaction, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 0.19% of the stock is owned by insiders.

Institutional investors have recently made changes to their positions in the company. Lynch & Associates IN lifted its position in shares of Johnson & Johnson by 0.9% in the second quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after acquiring an additional 841 shares in the last quarter. Oakbrook Investments LLC lifted its position in shares of Johnson & Johnson by 7.4% in the second quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after acquiring an additional 9,375 shares in the last quarter. Trexquant Investment LP purchased a new position in shares of Johnson & Johnson in the first quarter valued at about $1,731,000. Bollard Group LLC lifted its position in shares of Johnson & Johnson by 5.0% in the second quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after acquiring an additional 459 shares in the last quarter. Finally, Adams Diversified Equity Fund Inc. lifted its position in shares of Johnson & Johnson by 278.0% in the second quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after acquiring an additional 177,900 shares in the last quarter. Institutional investors and hedge funds own 65.90% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Get a free copy of the Zacks research report on Johnson & Johnson (JNJ)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with Analyst Ratings Network's FREE daily email newsletter.